These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 18843980)

  • 1. [Prognostic factors analysis for R-CHOP regimen therapy in diffuse large B cell lymphoma].
    Shen Y; Yao Y; Li JM; Chen QS; You JH; Zhao HJ; Chen S; Shen ZX
    Zhonghua Xue Ye Xue Za Zhi; 2008 Apr; 29(4):252-7. PubMed ID: 18843980
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of gastrointestinal diffuse large B cell lymphoma in China: a 10-year retrospective study of 114 cases.
    Li X; Shen W; Cao J; Wang J; Chen F; Wang C; Zou S; Shen B; Zhao R; Li J; Shen Z
    Ann Hematol; 2012 Nov; 91(11):1721-9. PubMed ID: 22733613
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Evaluation of the impact of R-CHOP chemotherapy on efficacy, safety and prognosis in newly diagnosed diffuse large B-cell lymphoma patients and its prognostic impact: a multicenter retrospective study with long term follow-up].
    Cheng ZX; Zou SH; Li F; Li JM; Wang JM; Chen FY; Cao JN; Wang C; Wei Z; Cheng YF
    Zhonghua Xue Ye Xue Za Zhi; 2012 Apr; 33(4):257-60. PubMed ID: 22781712
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The comparison between CHOP and R-CHOP in primary gastric diffuse large B cell lymphoma.
    Sohn BS; Kim SM; Yoon DH; Kim S; Lee DH; Kim JH; Lee SW; Huh J; Suh C
    Ann Hematol; 2012 Nov; 91(11):1731-9. PubMed ID: 22752193
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A success story: how a single targeted-therapy molecule impacted on treatment and outcome of diffuse large B-cell lymphoma.
    Mian M; Augustin F; Kocher F; Gunsilius E; Willenbacher W; Zabernigg A; Zangerl G; Oexle H; Schreieck S; Schnallinger M; Fiegl M
    Anticancer Res; 2014 May; 34(5):2559-64. PubMed ID: 24778077
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum level of soluble tumor necrosis factor receptor 2 is associated with the outcome of patients with diffuse large B-cell lymphoma treated with the R-CHOP regimen.
    Nakamura N; Goto N; Tsurumi H; Takemura M; Kanemura N; Kasahara S; Hara T; Yasuda I; Shimizu M; Sawada M; Yamada T; Seishima M; Takami T; Moriwaki H
    Eur J Haematol; 2013 Oct; 91(4):322-31. PubMed ID: 23672298
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patients with diffuse large B cell lymphoma in partial response or stable disease after first-line R-CHOP: the prognostic value of the absolute lymphocyte count and impact of autologous stem cell transplantation.
    Hung MH; Yu YB; Huang YC; Liu HT; Hong YC; Hsiao LT; Liu JH; Gau JP; Chiou TJ; Chen PM; Tzeng CH; Liu CY
    Ann Hematol; 2012 Dec; 91(12):1907-15. PubMed ID: 22885989
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic relevance of pretreatment quality of life in diffuse large B-cell lymphoma patients treated with rituximab-CHOP: results from a prospective cohort study.
    Jung HA; Park S; Cho JH; Kim S; Ko YH; Kim SJ; Kim WS
    Ann Hematol; 2012 Nov; 91(11):1747-56. PubMed ID: 22739576
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD4(+) tumor infiltrating lymphocytes are prognostic and independent of R-IPI in patients with DLBCL receiving R-CHOP chemo-immunotherapy.
    Keane C; Gill D; Vari F; Cross D; Griffiths L; Gandhi M
    Am J Hematol; 2013 Apr; 88(4):273-6. PubMed ID: 23460351
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of prognostic models for patients with diffuse large B-cell lymphoma in the rituximab era.
    Huang YC; Liu CY; Lu HJ; Liu HT; Hung MH; Hong YC; Hsiao LT; Gau JP; Liu JH; Hsu HC; Chiou TJ; Chen PM; Tzeng CH; Yu YB
    Ann Hematol; 2013 Nov; 92(11):1513-20. PubMed ID: 23775580
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIV status does not impair the outcome of patients diagnosed with diffuse large B-cell lymphoma treated with R-CHOP in the cART era.
    Coutinho R; Pria AD; Gandhi S; Bailey K; Fields P; Cwynarski K; Wilson A; Papanastasopoulos P; Tenant-Flowers M; Webb A; Burns F; Marcus RE; Orkin C; Montoto S; Bower M
    AIDS; 2014 Mar; 28(5):689-97. PubMed ID: 24418826
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of therapeutic outcomes between surgical resection followed by R-CHOP and R-CHOP alone for localized primary intestinal diffuse large B-cell lymphoma.
    Lee HS; Park LC; Lee EM; Shin SH; Ye BJ; Oh SY; Song MK; Lee SM; Lee WS; Kang BW; Chang MH; Cho SG; Yahng SA; Yoon SS; Kwon JH; Kim YS
    Am J Clin Oncol; 2014 Apr; 37(2):182-7. PubMed ID: 23211226
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Comparison the efficacy and prognosis of different first-line treatment for elderly diffuse large B-cell lymphoma].
    Liu P; Jiang SY; He XH; Qin Y; Gui L; Zhou SY; Yang JL; Yang S; Wen TY; Shi YK
    Zhonghua Zhong Liu Za Zhi; 2020 Mar; 42(3):234-241. PubMed ID: 32252203
    [No Abstract]   [Full Text] [Related]  

  • 14. Similar outcomes in Asian and Western patients with diffuse large B-cell lymphoma treated with R-CHOP.
    Castillo JJ; Sinclair N; Beltrán BE; Song MK; Ilic I; Leppa S; Nurmi H; Seki R; Uccella S; Li JM; Treaba DO; Stachurski D; Butera JN
    Leuk Res; 2013 Apr; 37(4):386-91. PubMed ID: 23352640
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Comparative analysis of liver function in HBsAg-/HBcAb+ patients with diffuse large B-cell lymphoma treated with CHOP and R-CHOP regimens].
    Huang YH; He XH; Qin Y; Yang S; Lü Z; Dong M; Zhou SY; Liu P; Zhang CG; Yang JL; Shi YK
    Zhonghua Zhong Liu Za Zhi; 2012 May; 34(5):385-9. PubMed ID: 22883463
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The highest prognostic impact of LDH among International Prognostic Indices (IPIs): an explorative study of five IPI factors among patients with DLBCL in the era of rituximab.
    Park JH; Yoon DH; Kim DY; Kim S; Seo S; Jeong Y; Lee SW; Park CS; Huh J; Suh C
    Ann Hematol; 2014 Oct; 93(10):1755-64. PubMed ID: 25027115
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum lactate dehydrogenase with a systemic inflammation score is useful for predicting response and survival in patients with newly diagnosed diffuse large B-cell lymphoma.
    Jung SH; Yang DH; Ahn JS; Kim YK; Kim HJ; Lee JJ
    Acta Haematol; 2015; 133(1):10-7. PubMed ID: 24969101
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Analysis of prognostic risk factors in patients with diffuse large B-cell lymphoma].
    Yu ZP; Ding JH; Chen BA; Gao C; Wang LL; Chen Z
    Zhonghua Xue Ye Xue Za Zhi; 2011 Dec; 32(12):830-5. PubMed ID: 22339956
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HIV-infection impact on clinical-biological features and outcome of diffuse large B-cell lymphoma treated with R-CHOP in the combination antiretroviral therapy era.
    Baptista MJ; Garcia O; Morgades M; Gonzalez-Barca E; Miralles P; Lopez-Guillermo A; Abella E; Moreno M; Sancho JM; Feliu E; Ribera JM; Navarro JT
    AIDS; 2015 Apr; 29(7):811-8. PubMed ID: 25730510
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of CHOP for treatment of diffuse large B-cell lymphoma with different combination antiretroviral therapy regimens: SCULPT study.
    Wong AY; Marcotte S; Laroche M; Sheehan NL; Kukreti V; Routy JP; Lemieux B; Seki JT; Rouleau D; Tseng A
    Antivir Ther; 2013; 18(5):699-707. PubMed ID: 23640963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.